Emerging Resistance to Empiric Antimicrobial Regimens for Pediatric Bloodstream Infections in Malawi (1998-2017).
Anti-Bacterial Agents
/ therapeutic use
Bacteremia
/ drug therapy
Blood Culture
/ statistics & numerical data
Child, Preschool
Cross Infection
/ epidemiology
Drug Resistance, Multiple, Bacterial
Gram-Negative Bacterial Infections
/ drug therapy
Gram-Positive Bacterial Infections
/ drug therapy
Hospitalization
/ statistics & numerical data
Humans
Incidence
Infant
Malawi
/ epidemiology
Prevalence
Gram negative
antimicrobial resistance
neonatal
pediatric
sepsis
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
18 06 2019
18 06 2019
Historique:
received:
15
05
2018
accepted:
28
09
2018
pubmed:
3
10
2018
medline:
14
8
2020
entrez:
3
10
2018
Statut:
ppublish
Résumé
The adequacy of the World Health Organization's Integrated Management of Childhood Illness (IMCI) antimicrobial guidelines for the treatment of suspected severe bacterial infections is dependent on a low prevalence of antimicrobial resistance (AMR). We describe trends in etiologies and susceptibility patterns of bloodstream infections (BSI) in hospitalized children in Malawi. We determined the change in the population-based incidence of BSI in children admitted to Queen Elizabeth Central Hospital, Blantyre, Malawi (1998-2017). AMR profiles were assessed by the disc diffusion method, and trends over time were evaluated. A total 89643 pediatric blood cultures were performed, and 10621 pathogens were included in the analysis. Estimated minimum incidence rates of BSI for those ≤5 years of age fell from a peak of 11.4 per 1000 persons in 2002 to 3.4 per 1000 persons in 2017. Over 2 decades, the resistance of Gram-negative pathogens to all empiric, first-line antimicrobials (ampicillin/penicillin, gentamicin, ceftriaxone) among children ≤5 years increased from 3.4% to 30.2% (P < .001). Among those ≤60 days, AMR to all first-line antimicrobials increased from 7.0% to 67.7% (P < .001). Among children ≤5 years, Klebsiella spp. resistance to all first-line antimicrobial regimens increased from 5.9% to 93.7% (P < .001). The incidence of BSI among hospitalized children has decreased substantially over the last 20 years, although gains have been offset by increases in Gram-negative pathogens' resistance to all empiric first-line antimicrobials. There is an urgent need to address the broader challenge of adapting IMCI guidelines to the local setting in the face of rapidly-expanding AMR in childhood BSI.
Sections du résumé
BACKGROUND
The adequacy of the World Health Organization's Integrated Management of Childhood Illness (IMCI) antimicrobial guidelines for the treatment of suspected severe bacterial infections is dependent on a low prevalence of antimicrobial resistance (AMR). We describe trends in etiologies and susceptibility patterns of bloodstream infections (BSI) in hospitalized children in Malawi.
METHODS
We determined the change in the population-based incidence of BSI in children admitted to Queen Elizabeth Central Hospital, Blantyre, Malawi (1998-2017). AMR profiles were assessed by the disc diffusion method, and trends over time were evaluated.
RESULTS
A total 89643 pediatric blood cultures were performed, and 10621 pathogens were included in the analysis. Estimated minimum incidence rates of BSI for those ≤5 years of age fell from a peak of 11.4 per 1000 persons in 2002 to 3.4 per 1000 persons in 2017. Over 2 decades, the resistance of Gram-negative pathogens to all empiric, first-line antimicrobials (ampicillin/penicillin, gentamicin, ceftriaxone) among children ≤5 years increased from 3.4% to 30.2% (P < .001). Among those ≤60 days, AMR to all first-line antimicrobials increased from 7.0% to 67.7% (P < .001). Among children ≤5 years, Klebsiella spp. resistance to all first-line antimicrobial regimens increased from 5.9% to 93.7% (P < .001).
CONCLUSIONS
The incidence of BSI among hospitalized children has decreased substantially over the last 20 years, although gains have been offset by increases in Gram-negative pathogens' resistance to all empiric first-line antimicrobials. There is an urgent need to address the broader challenge of adapting IMCI guidelines to the local setting in the face of rapidly-expanding AMR in childhood BSI.
Identifiants
pubmed: 30277505
pii: 5113431
doi: 10.1093/cid/ciy834
pmc: PMC6579959
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-68Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NHGRI NIH HHS
ID : U41 HG006941
Pays : United States
Informations de copyright
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Infect. 2001 Jan;42(1):44-9
pubmed: 11243753
Chest. 1992 Jun;101(6):1644-55
pubmed: 1303622
Ann Trop Paediatr. 2005 Jun;25(2):101-10
pubmed: 15949198
Ann Trop Med Parasitol. 2006 Jun;100(4):283-96
pubmed: 16762109
Vaccine. 2006 Sep 11;24(37-39):6232-9
pubmed: 16806603
Clin Infect Dis. 2008 Apr 1;46(7):963-9
pubmed: 18444810
Pediatr Infect Dis J. 2009 Jan;28(1 Suppl):S19-21
pubmed: 19106758
Genome Res. 2009 Dec;19(12):2279-87
pubmed: 19901036
PLoS One. 2010 May 04;5(5):e10452
pubmed: 20454611
BMC Pediatr. 2010 Jun 04;10:39
pubmed: 20525358
Clin Microbiol Infect. 2010 Aug;16(8):1062-9
pubmed: 20670288
Bull World Health Organ. 2010 Oct 1;88(10):746-53
pubmed: 20931059
Health Policy Plan. 2012 Jul;27 Suppl 3:iii88-103
pubmed: 22692419
Clin Infect Dis. 2012 Oct;55(7):967-75
pubmed: 22718774
J Antimicrob Chemother. 2013 Sep;68(9):2140-3
pubmed: 23645586
Pediatr Infect Dis J. 2014 Jun;33(6):560-5
pubmed: 24378940
PLoS One. 2014 Mar 13;9(3):e90990
pubmed: 24626194
PLoS One. 2014 Mar 18;9(3):e92226
pubmed: 24643091
Emerg Infect Dis. 2014 Nov;20(11):1957-9
pubmed: 25340988
PLoS Negl Trop Dis. 2015 Apr 24;9(4):e0003748
pubmed: 25909750
Nat Genet. 2016 Oct;48(10):1211-1217
pubmed: 27548315
Lancet Glob Health. 2016 Oct;4(10):e676-7
pubmed: 27633421
Pediatr Infect Dis J. 2017 Dec;36(12):e328-e333
pubmed: 28263245
BMJ Open. 2017 Jul 2;7(6):e016283
pubmed: 28674145
Lancet Infect Dis. 2017 Oct;17(10):1042-1052
pubmed: 28818544
Afr J Lab Med. 2017 Jun 21;6(1):638
pubmed: 28879156
Clin Infect Dis. 2018 Feb 1;66(4):489-493
pubmed: 29020273
Lancet Respir Med. 2018 Mar;6(3):223-230
pubmed: 29508706
Emerg Infect Dis. 2018 May;24(5):841-851
pubmed: 29664370